|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions

News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia


Market Summary
News
IPOs

Company Profiles

Companies
Events

Research Store

Biotech Events
Post an Event

Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/22/2007 12:53:25 PM
WALTHAM, Mass.--(BUSINESS WIRE)--Artisan Pharma, Inc. today announced that Gary Shearman, Ph.D. has joined the board of directors of Artisan Pharma, Inc., bringing with him more than 25 years of senior management and leadership experience in the pharmaceutical and venture capital industries.
Dr. Shearman is currently President and Chief Executive Officer of Neuro-Hitech, Inc. (www.neurohitech.com) (NASDAQ:NHPI), a public biopharmaceutical company focused on developing innovative new drugs for the treatment of neurodegenerative diseases. He is also Chairman of the board of directors of Nereus Pharmaceuticals, Inc. (www.nereuspharm.com), a privately held biotechnology company. From 2001 – 2007, Dr. Shearman was Chairman and Managing Director of HBM Advisors USA, LLC, a provider of investment advisory services for HBM Partners (Cayman) Ltd. the investment manager for all HBM vehicles including HBM Bioventures and HBM Biocapital. Prior to his tenure at HBM, Dr. Shearman held a number of senior positions in the pharmaceutical industry, most recently as Senior Vice President of Pharmaceutical Drug Development and Deputy Head of Research and Development at Rhone Poulenc Rorer (now Sanofi-Aventis). While at Rhone Poulenc, he was intimately involved with the development of LOVENOX®, the low molecular weight heparin anticoagulant, experience which will be fully leveraged at Artisan.
|
|
|
|
|
|
|
|
|
|
|